Ligand Pharmaceuticals (NASDAQ: LGND) announced that a subsidiary has entered into an exclusive license agreement with ParinGenix Inc. under which ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE